Hua Medicine (Shanghai) Ltd.

SEHK:2552 Stok Raporu

Piyasa değeri: HK$1.7b

Hua Medicine (Shanghai) Temettü

Temettü kriter kontrolleri 0/6

Hua Medicine (Shanghai) does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-0.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi-0.1%
Gelecekteki Temettü Verimi0%
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Nov 17
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

Aug 28
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

Jan 06
We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Aug 02
We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Apr 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Sep 23
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Jun 24
We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Mar 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Feb 21
Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Jan 25
Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

Dec 21
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if 2552's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if 2552's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

Hua Medicine (Shanghai) Piyasaya Karşı Temettü Getirisi
2552 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (2552)n/a
Pazarın Alt %25'i (HK)3.2%
Pazarın En İyi %25'i (HK)7.9%
Sektör Ortalaması (Pharmaceuticals)3.7%
Analist tahmini (2552) (3 yıla kadar)0%

Önemli Temettü: Unable to evaluate 2552's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate 2552's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate 2552's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as 2552 has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin